Estradiol–Receptor–Autophagy Axis: Mechanistic Insights into Organ Protection During Perimenopause

Study Background and Research Question

Declining levels of estradiol, the principal estrogen in premenopausal women, have long been implicated in the pathogenesis of age-related diseases during perimenopause. Epidemiological surveys consistently report increased incidence of cardiovascular, renal, and metabolic disorders in this population, coinciding with hormonal shifts. However, the precise molecular mechanisms underlying estradiol’s organ-protective effects, particularly the role of estrogen receptor signaling and autophagy, have remained incompletely defined. The recent study by Yunjun Ruan et al. (reference study) addresses this gap by integrating human cohort analysis with experimental mouse models and network pharmacology to dissect the estrogen receptor–autophagy axis in perimenopausal aging.

Key Innovation from the Reference Study

The critical innovation of this research is the comprehensive demonstration that estradiol, acting via distinct estrogen receptor pathways, orchestrates autophagy to confer protection in the heart, aorta, and kidneys during perimenopausal aging. By correlating clinical data with rigorous preclinical models, the study directly links serum estradiol levels to multi-organ health outcomes and identifies molecular targets that mediate these effects. This work establishes a mechanistic platform for precision hormone therapy and advances understanding of how estrogen receptor subtype signaling (ERα and ERβ) differentially regulates autophagic processes in target tissues.

Methods and Experimental Design Insights

The investigators employed a multi-modal approach. First, large-scale data from the National Health and Nutrition Examination Survey (NHANES) were used to analyze associations between circulating estradiol and risks for hypertension, kidney disease, diabetes, and hypercholesterolemia. To experimentally validate these correlations, a perimenopausal mouse model was established, simulating human hormonal decline. Mice received estrogen replacement therapy, and tissue histopathology of the heart, aorta, and kidneys was systematically evaluated. Network pharmacology was applied to identify gene targets shared between estradiol and fibrosis pathways, with a particular focus on autophagy-related genes. Functional validation was achieved using receptor-specific inhibitors (targeting ERα and ERβ) and autophagy blockers in vivo, allowing dissection of the signaling hierarchy underlying organ protection.

Protocol Parameters

• Estradiol administration in mice: Begin treatment upon confirmation of perimenopausal status; dosing and duration tailored to mimic physiological levels observed in perimenopausal women.
• Histopathological assessment: Harvest heart, aorta, and kidney tissues post-treatment for fibrosis and structural evaluation.
• Network pharmacology workflow: Integrate transcriptomic and proteomic data to identify estradiol-modulated targets involved in fibrosis and autophagy.
• Use of receptor/autophagy inhibitors: Apply ERα, ERβ, and autophagy inhibitors to estrogen-treated mice to verify pathway specificity of observed protective effects.

Core Findings and Why They Matter

The study found that lower serum estradiol was strongly associated with increased risks of hypertension, kidney disease, diabetes, and hypercholesterolemia in women, as determined from NHANES cohort analyses (reference study). In the perimenopausal mouse model, estrogen treatment markedly reduced fibrosis and improved tissue integrity in the heart, aorta, and kidneys. These beneficial effects were recapitulated by the activation of autophagy and were abolished when estrogen receptor or autophagy signaling was pharmacologically inhibited, confirming the requirement for both receptor specificity and downstream autophagic flux.

Network pharmacology identified key targets within the PI3K/Akt/mTOR signaling pathway, suggesting that estradiol’s engagement of ERα and ERβ orchestrates gene programs promoting cellular homeostasis and tissue repair. The distinction between ERα and ERβ signaling was highlighted by receptor-specific inhibitor experiments: ERα primarily mediated vascular and renal protection, while ERβ contributed to cardiac effects, underscoring the potential for receptor-selective interventions. Importantly, the organ-protective actions of estradiol were linked to increased autophagy, a process critical for clearing damaged proteins and organelles under metabolic stress.

Comparison with Existing Internal Articles

Recent internal literature, such as the article "Estradiol–Receptor–Autophagy Axis in Organ Protection During Perimenopause", corroborates these findings: declining estradiol impairs autophagy via estrogen receptor pathways, predisposing to cardiovascular and renal dysfunction. Similarly, "Estradiol, Estrogen Receptors, and Autophagy: New Frontiers in Organ Protection" explores how 17 beta-estradiol modulates receptor subtype signaling and autophagy in translational models, directly paralleling the mechanistic insights of the reference study. The present research extends these concepts by integrating human cohort data, precise receptor pharmacology, and network-level target identification, providing robust translational guidance for future interventions.

Further, the internal review "Estradiol–Autophagy Axis: Strategic Advances for Translational Research" highlights the importance of using high-purity estradiol reagents and aligns with the current study’s emphasis on receptor-selective and autophagy-dependent mechanisms, underscoring the evolving landscape of estrogen research in age-related organ protection.

Limitations and Transferability

Key limitations include the inherent constraints of cross-sectional human cohort data, which, while robustly associative, cannot fully establish causality. The mouse model recapitulates many, but not all, features of the human perimenopausal transition, and differences in estradiol pharmacokinetics and tissue distribution may affect translatability. Although receptor-specific and autophagy inhibitors provide mechanistic clarity, off-target effects and compensatory pathways in vivo could influence outcomes. Nonetheless, the convergence of molecular, cellular, and organismal data across species enhances confidence in the generalizability of the estradiol–receptor–autophagy axis for organ protection.

Research Support Resources

For researchers aiming to replicate or extend these workflows, validated reagents are critical. Estradiol (SKU A8425, APExBIO) is widely used in experimental models to investigate estrogen receptor signaling, ERα/ERβ-selective pathways, and autophagy modulation. Available as a 10 mM solution in DMSO or as powder, it supports flexible protocol design for both in vitro and in vivo studies. As highlighted in translational reviews, rigorous sourcing and characterization of 17 beta-estradiol facilitate reproducible research in organ protection and metabolic disease modeling.